<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557735</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-TMA-314</org_study_id>
    <secondary_id>2020-000761-16</secondary_id>
    <nct_id>NCT04557735</nct_id>
  </id_info>
  <brief_title>Study of Ravulizumab in Pediatric Participants With HSCT-TMA</brief_title>
  <official_title>A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of&#xD;
      ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to &lt;&#xD;
      18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week&#xD;
      off-treatment follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with TMA Response</measure>
    <time_frame>26 weeks (treatment period)</time_frame>
    <description>TMA Response is defined as platelet count ≥ 50,000/mm^3, lactate dehydrogenase &lt; 1.5 x upper limit of normal, and ≥ 50% reduction from baseline in proteinuria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To TMA Response</measure>
    <time_frame>26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with TMA Relapse</measure>
    <time_frame>26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who die due to any cause during the study, with the exception of death due to underlying disease progression or relapse</measure>
    <time_frame>26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Platelet Response ≥ 100,000/mm^3 without transfusion support</measure>
    <time_frame>26 weeks (treatment period) and 52 weeks (includes treatment period and off-treatment follow-up period)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thrombotic Microangiopathy</condition>
  <arm_group>
    <arm_group_label>Ravulizumab plus Best Supportive Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ravulizumab plus Best Supportive Care as background therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravulizumab</intervention_name>
    <description>Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.</description>
    <arm_group_label>Ravulizumab plus Best Supportive Care</arm_group_label>
    <other_name>Ultomiris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).</description>
    <arm_group_label>Ravulizumab plus Best Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 1 month of age up to &lt; 18 years of age at the time of signing the informed consent.&#xD;
&#xD;
          2. Received HSCT within the past 6 months.&#xD;
&#xD;
          3. Diagnosis of TMA that persists despite initial management of any triggering condition.&#xD;
&#xD;
          4. Body weight ≥ 5 kilograms.&#xD;
&#xD;
          5. Female participants of childbearing potential and male participants with female&#xD;
             partners of childbearing potential must use highly effective contraception starting at&#xD;
             Screening and continuing until at least 8 months after the last dose of ravulizumab.&#xD;
&#xD;
          6. Participants must be vaccinated against meningococcal infections if clinically&#xD;
             feasible, according to institutional guidelines for immune reconstitution after HSCT.&#xD;
             Participants must be re-vaccinated against Haemophilus influenzae type b and&#xD;
             Streptococcus pneumoniae if clinically feasible, according to institutional guidelines&#xD;
             for immune reconstitution after HSCT. All participants should be administered coverage&#xD;
             with prophylactic antibiotics according to institutional post-transplant infection&#xD;
             prophylaxis guidances, including coverage against Neisseria meningitidis for at least&#xD;
             2 weeks after meningococcal vaccination. Participants who cannot receive meningococcal&#xD;
             vaccine should receive antibiotic prophylaxis coverage against Neisseria meningitidis&#xD;
             the entire Treatment Period and for 8 months following the final dose of ravulizumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known familial or acquired 'a disintegrin and metalloproteinase with a thrombospondin&#xD;
             type 1 motif, member 13' deficiency (activity &lt; 5%).&#xD;
&#xD;
          2. Known Shiga toxin-related hemolytic uremic syndrome.&#xD;
&#xD;
          3. Positive direct Coombs test.&#xD;
&#xD;
          4. Diagnosis or suspicion of disseminated intravascular coagulation.&#xD;
&#xD;
          5. Known bone marrow/graft failure.&#xD;
&#xD;
          6. Diagnosis of veno-occlusive disease.&#xD;
&#xD;
          7. Human immunodeficiency virus (HIV) infection (evidenced by HIV-1 or HIV-2 antibody&#xD;
             titer).&#xD;
&#xD;
          8. Unresolved meningococcal disease.&#xD;
&#xD;
          9. Presence or suspicion of sepsis (treated or untreated) within 7 days prior to&#xD;
             Screening.&#xD;
&#xD;
         10. Pregnancy or breastfeeding.&#xD;
&#xD;
         11. Hypersensitivity to murine proteins or to 1 of the excipients of ravulizumab.&#xD;
&#xD;
         12. Previously or currently treated with a complement inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Osakasayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Setagaya-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombotic Microangiopathy (TMA)</keyword>
  <keyword>Ultomiris</keyword>
  <keyword>Ravulizumab</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ravulizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

